APA (7th ed.) Citation

Brose, M. S., Capdevila, J., Elisei, R., Bastholt, L., Führer-Sakel, D., Leboulleux, S., . . . Schlumberger, M. (2024). Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy. Endocrine-Related Cancer, 31(8), 12. https://doi.org/10.1530/ERC-23-0354

Chicago Style (17th ed.) Citation

Brose, Marcia S., et al. "Vandetanib in Locally Advanced or Metastatic Differentiated Thyroid Cancer Refractory to Radioiodine Therapy." Endocrine-Related Cancer 31, no. 8 (2024): 12. https://doi.org/10.1530/ERC-23-0354.

MLA (9th ed.) Citation

Brose, Marcia S., et al. "Vandetanib in Locally Advanced or Metastatic Differentiated Thyroid Cancer Refractory to Radioiodine Therapy." Endocrine-Related Cancer, vol. 31, no. 8, 2024, p. 12, https://doi.org/10.1530/ERC-23-0354.